Interview with CEO on Upcoming Clinical Trial A US survey found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.
I’ve been following AGN.c AGNPF (a clinical stage drug development company). This interview with their CEO gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3.
There’s clearly a huge opportunity in finding a solution to chronic cough and AGN is poised to find the solution.
https://www.youtube.com/watch?v=zpvV0-fELgc